NMDA NR2B antagonists for treatment
AssigneePfizer Inc.
InventorsBertrand L. Chenard, Mario Saltarelli, Frank S. Menniti
Life of this patent
Estimating the term…
Abstract
The invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of NR2B subunit selective NMDA antagonists. The disorders that can be treating by the invention include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and depression.
Claims2
A method of treating depression in a mammal, which method comprises administering to the mammal an amount of an NR2B subunit selective NMDA antagonist, which amount is effective in treating depression, wherein the NR2B subunit selective NMDA receptor antagonist is a compound of the formula
- or a pharmaceutically acceptable acid addition salt thereof,
- wherein:
- (a) R2 and R5 are taken separately and R1, R2, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7 and R5 is methyl or ethyl;
- or
- (b) R2 and R5 are taken together and are
- forming a chroman-4-ol ring, and R1, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7;
- R6 is
- R7 is methyl, ethyl, isopropyl or n-propyl;
- R8 is phenyl optionally substituted with up to three substituents independently selected from the group consisting of (C1-C6) alkyl, halo and CF3;
- X is O, S or (CH2)n;
- and
- n is 0, 1, 2, or 3.
Dependencies are inferred from the claim text.